CANCER – CHOLANGIOCARCINOMA

 

Opposing Actions of Endocannabinoids on Cholangiocarcinoma Growth                     (full – 2007)

http://www.jbc.org/content/282/17/13098.full

 

The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway                                                            (full – 2008)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2604798/?tool=pmcentrez

 

Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects      (abst – 2008)                                 http://gut.bmj.com/content/57/8/1140.abstract

 

Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling.                                                                          (full – 2010)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872061/?tool=pubmed

 

Recent advances in the regulation of cholangiocarcinoma growth                     (full – 2010)

http://ajpgi.physiology.org/content/299/1/G1.full

 

The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti- invasion activity at low concentration and apoptosis induction at high concentration. (abst – 2010)                                          http://www.ncbi.nlm.nih.gov/pubmed/19916793

 

Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor.                                                      (abst – 2011)           http://www.ncbi.nlm.nih.gov/pubmed/21464819

 

The novel cannabinoid receptor GPR55, inhibits cholangiocarcinoma growth (abst – 2011)

http://www.fasebj.org/cgi/content/meeting_abstract/25/1_MeetingAbstracts/1117.3?maxtoshow=&hits=80

&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=80&sortspec=date&resourcety  pe=HWCIT

 

Share a link for